WAVE Life Sciences Q2 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate, Sales $19.692M Miss $24.335M Estimate
Portfolio Pulse from Benzinga Newsdesk
WAVE Life Sciences (NASDAQ:WVE) reported Q2 2024 GAAP EPS of $(0.25), missing the $(0.21) estimate, and sales of $19.692M, missing the $24.335M estimate. Both EPS and sales showed declines compared to the same period last year.
August 08, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
WAVE Life Sciences reported Q2 2024 GAAP EPS of $(0.25), missing the $(0.21) estimate, and sales of $19.692M, missing the $24.335M estimate. Both EPS and sales showed declines compared to the same period last year.
The company's earnings and sales both missed analyst estimates and showed year-over-year declines, which is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100